BCL9

B-cell CLL/lymphoma 9 protein

18,053 patent compounds predicted against BCL9, 10,182 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL478100	0.53	15/20
SCHEMBL478136	0.53	14/20
SCHEMBL478039	0.49	13/20
SCHEMBL478086	0.46	13/20
SCHEMBL478167	0.43	10/20
Quercetin-3'-O-Phosphate (SCHEMBL118113)	0.67	9/20
SCHEMBL117682	0.65	9/20
SCHEMBL507435	0.60	8/20
SCHEMBL412179	0.54	8/20
Gossypetin (SCHEMBL157033)	0.73	7/20
Hydrochloric Acid (SCHEMBL72907)	0.49	7/20
Herbacetin (SCHEMBL872691)	0.67	6/20
SCHEMBL171665	0.48	6/20
SCHEMBL241094	0.48	6/20
SCHEMBL442344	0.47	6/20
SCHEMBL118236	0.44	6/20
SCHEMBL411999	0.41	5/20
SCHEMBL112968	0.32	5/20
SCHEMBL542953	0.49	4/20
SCHEMBL171529	0.44	4/20

Germline variants in BCL9 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full BCL9 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to BCL9 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia	PHASE3	COMPLETED
SPC2996 in Chronic Lymphocytic Leukaemia	PHASE1/PHASE2	COMPLETED
Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma	PHASE1/PHASE2	RECRUITING
Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma	PHASE2	RECRUITING
Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia	PHASE1/PHASE2	COMPLETED
DALY II Japan/MB-CART2019.1 for DLBCL	PHASE2	RECRUITING
Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL	PHASE2	ACTIVE_NOT_RECRUITING
Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma	PHASE2	RECRUITING
CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma	PHASE1/PHASE2	RECRUITING
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma	PHASE1	ACTIVE_NOT_RECRUITING
Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies	PHASE1	UNKNOWN
Safe Accelerated Venetoclax Escalation in CLL	PHASE1	ACTIVE_NOT_RECRUITING
T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies	PHASE1	COMPLETED
Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma	PHASE1	UNKNOWN
CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT	PHASE1	UNKNOWN
Safety and Efficacy Evaluation of IM19 Cells	PHASE1	UNKNOWN
Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA	PHASE1	RECRUITING
PS-341 in Treating Patients With Hematologic Cancer	PHASE1	COMPLETED
Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma	PHASE1	WITHDRAWN
Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma	PHASE1	COMPLETED
MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)	PHASE1	ACTIVE_NOT_RECRUITING
A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies	EARLY_PHASE1	UNKNOWN
Notch 1 Mutation in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patient	nan	NOT_YET_RECRUITING
Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch	nan	NO_LONGER_AVAILABLE
Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program	nan	COMPLETED
French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma in Real-World Settings	nan	ACTIVE_NOT_RECRUITING
Determinants of the Response to BTK Degraders (BTKd) in Chronic Lymphocytic Leukemia	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a BCL9 binder may also engage these)

Protein	Name	Similarity
Q9D219	—	1.000	Q9D219 →
Q67FY3	—	1.000	Q67FY3 →
BCL9L	B-cell CLL/lymphoma 9-like protein (B-cell ly	0.997	landscape →
Q67FY2	—	0.996	Q67FY2 →
Q9R050	—	0.993	Q9R050 →
EP300	Histone acetyltransferase p300	0.992	landscape →
P0CB49	—	0.992	P0CB49 →
P40645	—	0.992	P40645 →
B2RWS6	—	0.991	B2RWS6 →
Q9R0I7	—	0.991	Q9R0I7 →
D3YWE6	—	0.991	D3YWE6 →
Q9CYZ8	—	0.990	Q9CYZ8 →
Q9BTA9	—	0.990	Q9BTA9 →
Q961D9	—	0.990	Q961D9 →
Q8R5I7	—	0.989	Q8R5I7 →
Q7ZUK7	—	0.989	Q7ZUK7 →
Q14686	—	0.989	Q14686 →
O35126	—	0.989	O35126 →
A3RK74	—	0.989	A3RK74 →
P81877	—	0.988	P81877 →
Q9P267	—	0.988	Q9P267 →
P40647	—	0.988	P40647 →
A2AJK6	—	0.988	A2AJK6 →
A0A0G2JTZ2	—	0.988	A0A0G2JTZ2 →
O14497	—	0.988	O14497 →
A3RK75	—	0.988	A3RK75 →
P34545	—	0.988	P34545 →
Q810W5	—	0.988	Q810W5 →
Q6EUW2	—	0.988	Q6EUW2 →
Q5RCU4	—	0.988	Q5RCU4 →